September 21, 2014 5:47 PM ET

Biotechnology

Company Overview of Lux Biosciences, Inc.

Company Overview

Lux Biosciences, Inc., a biotechnology company, engages in the development and commercialization of medications for ophthalmic diseases in the United States and internationally. Its products comprise LUVENIQ, an oral form of calcineurin inhibitor voclosporin, which is used for the treatment of non-infectious uveitis; LX214, a topical formulation that contains mixed nanomicelles of voclosporin for ophthalmic use; LX212, a bioerodible polymer implant containing voclosporin; and LX213, a bioerodible/isotechnika implant. The company was incorporated in 2005 and is based in Jersey City, New Jersey.

3 Second Street

Harborside Financial Center Plaza 10

14th Floor

Jersey City, NJ 07302

United States

Founded in 2005

Phone:

201-946-0551

Fax:

201-946-0552

Key Executives for Lux Biosciences, Inc.

Chief Executive Officer
Age: 58
Co-Founder and Senior Vice President of Project Planning & Analysis
Co-Founder and Chief Medical Officer
Co-Founder and Chief Operating Officer
President of Europe Region and Managing Director of Lux Biosciences GmbH
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Metabolic Solutions Development Company, LLC United States
Phage International, Inc. United States
Biomedical Development Corporation United States
3D Biomatrix Inc. United States
ImmuneWorks, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lux Biosciences, Inc., please visit www.luxbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.